Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Alpha Teknova yesterday. The company’s shares closed yesterday at $6.37.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Hewitt is an analyst with an average return of -1.6% and a 44.33% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Repligen, Omnicell, and Ligand Pharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alpha Teknova with a $7.50 average price target.
The company has a one-year high of $10.37 and a one-year low of $3.94. Currently, Alpha Teknova has an average volume of 274.5K.
Read More on TKNO:
Disclaimer & DisclosureReport an Issue
- Analysts Predict Up to 840% Jump for These 2 ‘Strong Buy’ Penny Stocks
- Alpha Teknova: Solid Q2 Performance but Modest Growth Outlook and High Valuation Justify Hold Rating
- new option listings on August 14th
- Alpha Teknova’s Earnings Call: Growth Amid Challenges
- Teknova’s Strong Execution and Financial Progress Justify Buy Rating
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Blackrock%20Inc_%20logo%20on%20building-%20by%20Tada%20Images%20via%20Shutterstock.jpg)
/2d%20illustration%20of%20Cloud%20computing%20by%20Blackboard%20via%20Shutterstock.jpg)
/Amazon_com%20Inc_%20storefront%20by-%20%20Markus%20Mainka%20via%20Shutterstock.jpg)